RheoGene, Inc. Grants Ichor Medical Systems, Inc. A Commercial License To Develop A Regulated Gene Therapy For Multiple Sclerosis Using The RheoSwitch® Therapeutic System
2/9/2006 2:09:51 PM
RheoGene, Inc., announced today that it has granted a commercial license to Ichor Medical Systems for use of its RheoSwitch® Therapeutic System (RTS) in combination with Ichor Medical Systems’ proprietary TriGrid™ Delivery System electroporation technology to develop a gene therapy product for multiple sclerosis. The agreement also grants Ichor an option to use RTS in two additional indications. Ichor has also granted an option for RheoGene to license Ichor’s TriGrid™ Delivery System to develop proprietary therapeutics.
comments powered by